Posts tagged “Chimerix ”
Chimerix, the Durham-based drug company working on experimental medicine that could save the life of a seven-year-old Josh Hardy, was granted approval by the U.S. Food and Drug Administration to administer the drug to the boy in March. On Wednesday, his mother said he is doing well and going home.
Durham firm's good FDA news; Chimerix eyes $200M; SEAL Innovation expands; Snapchat adds chat; eBay settles antitrust case
In today's Bulldog blog roundup of technology and life science news, get the latest about drug firm Parion Sciences, a $200 million stock offering from Chimerix, details about Raleigh-based startup SEAL Innovation's expansion, Snapchat finally adds chat, and eBay settles an antitrust case.
A spate of Triangle life science IPOs raised more total money than those in Boston and New York in 2013, and more followed early this year. Has this open IPO window affected biotech and life science fundraising in the Triangle? Will the window remain open? One area VC suggests we may look back on 2010-2015 as a watershed time for the regional industry.
Chimerix, the Durham-based drug company working on experimental medicine that could save the life of a seven-year-old Virginia child, was granted approval by the U.S. Food and Drug Administration to administer the drug to the boy, the company said Tuesday evening.
Quintiles led the class of Triangle IPOs in the last year at nearly $1 billion in value, but ChannelAdvisor's stock is showing remarkable strength. So is Aerie Pharmaceuticals. With Scynexis filing to go public Thursday, WRALTechWire updates what has happened on the stock "exit route" for regional firms and how their stocks have fared since.
Finding the right chemistry is crucial to biotech deals, as two major life science partnerships in the Triangle have shown this year: GSK and Liquidia; Merck and Chimerix.
In exchange for exclusive worldwide license and funding the drug development and commercialization costs, Merck will pay Chimerix $17.5 million on top of royalties on future sales and milestone payments of up to $151 million.
Chimerix fought the award of a sole-source contract for a potential smallpox treatment to another firm and convinces the government agency involved to overturn it. Now, Chimerix can compete for a lucrative deal, CEO says.